The genotoxicity / mutagenicity testing services market is anticipated to grow at a CAGR of about 7%, till 2035, claims Roots Analysis 

Published: April 2023

Driven by the stringent regulatory guidelines issued to ensure safety of end-user and the growing pipeline of healthcare products, the demand for genotoxicity / mutagenicity testing has grown considerably, creating lucrative opportunities for service providers in this domain

Roots Analysis has announced the addition of Genotoxicity Testing Market report to its list of offerings. 

Exposure to genotoxic and mutagenic compounds can cause mutations in humans, eventually leading to a number of oncological and genetic disorders. Therefore, testing of genotoxicity / mutagenicity is an essential to assess the safety of products, by ensuring the lack of certain particles that can negatively impact human health. These tests are currently being used across several industries, including healthcare, chemical, cosmetic, agriculture and food. 

To order this 190+ slide report, which features 90+ figures and 200+ tables, please visit

Key Market Insights 

More than 80 organizations claim to offer genotoxicity / mutagenicity testing services, globally 
Majority (49%) of the stakeholders engaged in this market have headquarters in Asia-Pacific, followed by those based in North America (30%) and Europe (21%). Further, this segment of the industry is dominated by the presence of mid-sized players (51-200 employees), which represent 43% of the service providers.

~360 articles related to genotoxicity and mutagenicity, have been published, since 2018
More than 45% of the total articles were observed to have been published post-2020. Popular journals, which have published multiple articles, include (in alphabetical order) International Journal of Environmental Research and Public Health, Molecules, Nanomaterials, Toxicology Reports and Toxicology Research.

Around 280 grants have been awarded in this industry, during the period 2018-2022 
Overall, USD 210 million was received via grants awarded for research focused genotoxicity and mutagenicity testing, since 2018. Of the total, nearly 25% of the grants were / are being managed by National Institute of Environmental Health Sciences (NIEHS), followed by those managed by National Institute of Allergy and Infectious Diseases (NIAID) (22%) and National Cancer Institute (NCI) (12%).

Partnership activity within this domain has increased at a CAGR of ~10%, between 2018 and 2022 
More than 55% of the reported deals were established post 2020, with the maximum partnership activity (~50%) being reported in 2021. Further, acquisitions emerged as the most popular agreement model adopted by genotoxicity / mutagenicity testing service providers, representing over 60% of the total deals.

450+ patents related to genotoxicity and mutagenicity have been filed / granted since 2018
Close to 70% of the total patents were filed / granted in Asia-Pacific, highlighting the active innovation focused efforts ongoing in the region. Further, both industry as well as non-industry, players are active in patent filing activity for genotoxicity and mutagenicity testing.

North America is anticipated to capture a larger share of the genotoxicity / mutagenicity testing services market, by 2035
The global genotoxicity / mutagenicity testing services market is expected to be primarily driven by in vivo assays, till 2035. In addition, in the long term, majority of the market share is anticipated to be captured by comet assays (48%) followed by micronucleus assays (11%) and chromosomal aberration tests (7%).

You Can Download Free Sample PDF Copy of This Report At:

Key Questions Answered

  • What is genotoxicity and mutagenicity?
  • What are the key advantages offered by genotoxicity and mutagenicity testing?
  • What is the current market landscape of genotoxicity and mutagenicity testing service?
  • What is the need for outsourcing genotoxicity / mutagenicity testing to contract service providers?
  • What are the key trends related to grants offered for genotoxicity and mutagenicity testing?
  • What is the trend of publications related to genotoxicity / mutagenicity testing?
  • Across which industries can genotoxicity / mutagenicity testing be utilized?
  • What is the genotoxicity / mutagenicity testing services market likely to evolve?

The financial opportunity within the genotoxicity / mutagenicity testing services market has been analyzed across the following segments:

  • Type of Assay
    • In vivo Assays
    • In vitro Assays
    • Non-GLP / Screening Assays
  • Assay / Test Offered
    • Comet Assays
    • Micronucleus Assays
    • Chromosomal Aberration Tests
    • Genetic Mutation Tests
    • Other Tests
  • End User Industry
    • Chemical Industry
    • Healthcare Industry
    • Agriculture Industry
    • Cosmetic Industry
    • Other Industries
  • Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific 
    • Latin America
    • MENA

The research also includes profiles of key players (listed below) engaged in the genotoxicity / mutagenicity testing services market; each profile features an overview of the company, details related to its financial information (if available), service portfolio, recent developments, and an informed future outlook.

  • Aurigene Pharmaceutical Services
  • Charles River Laboratories
  • GLR Laboratories
  • Labcorp
  • LSIM Safety Institute
  • Sai Life Sciences
  • Syngene

For additional details, please email at 

You may also be interested in the following titles:

  1. Liposome Development and Manufacturing Services Market
  2. DNA and Gene Cloning Services Market
  3. Container Closure Integrity Testing Services Market

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry